Analyst Caitlin Cronin of Canaccord Genuity maintained a Buy rating on SI-Bone (SIBN – Research Report), retaining the price target of $25.00.
Caitlin Cronin’s rating is based on SI-Bone’s outstanding performance in the recent quarter, where the company exceeded expectations in both revenue and profitability metrics. The company achieved a second consecutive quarter of adjusted EBITDA positivity and reported significant growth in surgeon engagement, with a record number of new physicians and an increase in the number of surgeons performing multiple procedure types. Additionally, SI-Bone’s recent product launches have outperformed expectations, contributing to its strong market position.
Caitlin Cronin also highlights SI-Bone’s strategic growth initiatives, including expanding its sales force and increasing territory productivity, which are expected to drive further revenue growth. The company’s guidance for 2025 reflects a conservative outlook, with anticipated revenue growth of 16-18% and gross margins of 78%. Moreover, SI-Bone’s operations are largely insulated from potential tariff impacts, and its procedures are considered recession-resistant, providing a stable foundation for future growth. These factors collectively support the Buy rating, as SI-Bone continues to build a sustainable growth engine in the sacropelvic solutions market.
In another report released today, Needham also reiterated a Buy rating on the stock with a $24.00 price target.
SIBN’s price has also changed slightly for the past six months – from $14.550 to $14.250, which is a -2.06% drop .